- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02061137
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome (FINGORETT)
A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome.
Study Overview
Detailed Description
Rett syndrome is a neurodevelopmental disorder characterized by normal early psychomotor development followed by the loss of psychomotor and acquired purposeful hand skills and the onset of stereotyped movement of the hands and gait disturbance. The gene was discovered in 1999 and the disease was found to be caused by a mutation of the methyl-CpGbinding protein 2 (MeCP2). However, in many ways this clinically peculiar condition remains a mystery, with no clear correlations between the gene mutation and abnormal biological markers, neuropathology and/or unique clinical symptoms and signs.
Rett syndrome is an X-linked (Xq28) dominant postnatal severe neurodevelopmental disorder which is the second most common cause for genetic mental retardation in girls and the first pervasive disorder with a known genetic basis. Its incidence is between 1/10,000-15000 live births. The classical variant is characterized by apparently normal development for the first 6-18 months accompanied usually with early deceleration of head growth, followed by period of regression of motor and language skills, hand stereotypes, seizures, autonomic dysfunction and other neurological and related symptoms.
Repeated observations and experiments of the mouse models in several laboratories led to the appreciation of the role of BDNF in the disease pathophysiology. BDNF is a neurotrophic factor playing a major role in neurogenesis, neuronal survival, differentiation, and maturation during early development as well as in synaptic function and plasticity throughout life. Abnormalities in BDNF homeostasis are believed to contribute to the neurological phenotype and pathophysiology in part of the symptoms in methyl-CpG binding protein 2(Mecp2) null mice that show progressive deficits in its expression during the symptomatic stage.
FTY720 (Gilenya) is an orally active modulator of four of the five sphingosine-1 phosphate(S1P) receptors. FTY720 acts as 'super agonist' on the S1P receptor on thymocytes and lymphocytes, inducing uncoupling/internalization of that receptor.
A local study group (Yves-Alain Barde) found that FTY720 increases the levels of brain derived neurotrophic factor and improves symptoms of mice lacking MeCP2. In addition the volume of the striatum seemed to be higher (4 week old mice were treated in 4 days intervals with 0.1mg/kg body weight intraperitoneally).
Based on these results we intend to perform a phase I clinical,study to assess safety and efficacy of oral fingolimod (FTY720) in children with Rett Syndrome. Children will be included if being older than 6 years of age, fulfilling diagnostic criteria of Rett Syndrome in clinical Stages II -IV and having parents that do agree.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4056
- Department of Neuropediatrics - University Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children fulfilling diagnostic criteria (2001, Hagberg B et al. Eur. J. Paediatr. Neurol. 2002) of Rett Syndrome
- Stages II -IV Hagberg/ Witt-Engerström (Hagberg B, Witt-Engerström I. Am J Med Genet 1986, Hagberg B. Ment Retard Dev Disabil Res Rev 2002)
- Patients older than 6 years old (have had their 6th birthday)
- Written informed consent of parents/ of legal guardian
- Negative testing for pregnancy
- Positive confirmation of a MECP2 mutation
Exclusion Criteria:
- Any uncertainty about diagnosis of Rett Syndrome
- Patients younger than 6 years old (have not yet had their 6thbirthday)
- Additional associated neurological diseases such as a brain malformation
- Patient <15kg body weight at timepoint of screening
- Patients with negative varicella-zoster virus immunoglobulin G (IgG) antibodies
- Pregnancy or breastfeeding for girls in childbearing potential age
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rett syndrome, fingolimod (FTY720)
0.5 or 0.25mg Fingolimod daily
|
0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Levels of Brain derived neurotrophic factor (BDNF) in blood and cerebrospinal fluid before and under treatment
Time Frame: change of BDNF measured at Baseline, at first dose, at 6 and at 12 months after start of treatment.
|
change of BDNF measured at Baseline, at first dose, at 6 and at 12 months after start of treatment.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ludwig Kappos, Prof., Department of Neurology - University Hospital Basel - Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Syndrome
- Rett Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Immunosuppressive Agents
- Immunologic Factors
- Sphingosine 1 Phosphate Receptor Modulators
- Fingolimod Hydrochloride
Other Study ID Numbers
- CFTY720D2201T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rett's Syndrome
-
National Human Genome Research Institute (NHGRI)CompletedAutism | Asperger's Syndrome | Rett's DisorderUnited States
-
Neumedicines Inc.Department of Health and Human ServicesCompletedHematopoietic Syndrome Due to Acute Radiation SyndromeUnited States
-
Ministry of Public Health, Democratic Republic...National Institutes of Health (NIH); Oregon Health and Science University; National... and other collaboratorsCompletedNeurotoxicity Syndrome, Cassava | Neurotoxicity Syndrome, Cyanate | Neurotoxicity Syndrome, Cyanide | Neurotoxicity Syndrome, ThiocyanateCongo, The Democratic Republic of the
-
Mahidol UniversityCompletedSubacromial Impingement Syndrome | Shoulder Impingement Syndrome | Subacromial Pain Syndrome | Subacromial Impingement | Impingement Syndrome, ShoulderIndonesia
-
Cliniques universitaires Saint-Luc- Université...TerminatedMultiple Organ Dysfunction Syndrome | SEPTIC SHOCK | SEPSIS SYNDROMEBelgium
-
University of PennsylvaniaRecruitingCRS - Cytokine Release Syndrome | HLHUnited States
-
University of ManitobaTerminatedPatellofemoral Pain Syndrome | Anterior Knee Pain Syndrome | Patellofemoral SyndromeCanada
-
Massachusetts General HospitalUniversity of California, San DiegoNot yet recruitingAuto-Brewery Syndrome | Gut Fermentation SyndromeUnited States
-
University of NottinghamMedical Research Council; National Institute for Health Research, United KingdomRecruitingFrail Elderly Syndrome | Frailty | Frailty SyndromeUnited Kingdom
-
Riphah International UniversityCompleted
Clinical Trials on fingolimod (FTY720)
-
NovartisCompletedRenal InsufficiencyRussian Federation
-
NovartisCompletedMultiple SclerosisGreece, Russian Federation, Switzerland, Germany, Israel, Ireland, Belgium, Finland, United Kingdom, Netherlands, Canada, Romania, Hungary, Poland, Czech Republic, Australia, Estonia, France, Slovakia, South Africa, Sweden, Turkey
-
Novartis PharmaceuticalsCompletedMultiple SclerosisItaly, Belgium, Germany
-
Tianjin Medical University General HospitalCompletedStroke | Stroke, Acute | Cerebral Stroke | Ischemic Cerebrovascular Accident | Vascular AccidentChina
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsCompletedRelapsing Forms of Multiple SclerosisGermany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis RRMSGermany, Switzerland
-
NovartisCompletedMultiple SclerosisUnited States, Turkey, Romania, United Kingdom, Poland, Austria, Canada, Australia
-
Novartis PharmaceuticalsActive, not recruitingRelapsing Multiple Sclerosis (RMS)China
-
The Methodist Hospital Research InstituteEnrolling by invitationKidney Failure, Chronic | Kidney Transplant Rejection | Graft Rejection | Kidney Transplant; Complications | Kidney Transplant Failure | Kidney Transplant Failure and Rejection | Interstitial FibrosisUnited States